Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2019 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results

BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 26, 2019 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 23, 2019 08:00 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting

BOTHELL, Wash., April 23, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 22, 2019 16:34 ET | Source: Alder BioPharmaceuticals, Inc.

U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab

BOTHELL, Wash., April 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 19, 2019 16:19 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., April 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 12, 2019 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., April 12, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 08, 2019 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer

BOTHELL, Wash., April 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 02, 2019 08:00 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference

BOTHELL, Wash., April 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
March 05, 2019 08:00 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference

BOTHELL, Wash, March 05, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
March 04, 2019 18:48 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares

BOTHELL, Wash., March 04, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right